Reprieve Cardiovascular Secures $42 Million Series A Financing for Intelligent Fluid Management in Heart Failure
Reprieve Cardiovascular, Inc., a trailblazing company dedicated to innovating intelligent automated diuretic and fluid management solutions for acute decompensated heart failure (ADHF) treatment, has successfully raised $42 million in a successful series A financing round. The funding, co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures, marks a significant milestone for the company, propelling its clinical and development programs, including the ongoing FASTR trial and an upcoming pivotal trial.
Heart failure affects over 6.7 million Americans today, with ADHF causing unplanned office visits, emergency room trips, or hospitalizations due to sudden or gradual onset symptoms. Recognizing the critical need for advanced treatment options, Reprieve Cardiovascular is on a mission to transform heart failure care.
The Reprieve System aims to personalize decongestion management effectively. By monitoring physiological parameters such as urine output, the system delivers personalized diuretic dosing and fluid replacement for ADHF patients. This intelligent approach seeks to improve patient outcomes, prevent hospital readmissions, and address the challenges posed by the standard diuretic treatment option, which has remained largely unchanged for 60 years.
Mark Pacyna, CEO of Reprieve Cardiovascular, emphasized the significance of bringing intelligent decongestion management to heart failure patients. The Reprieve System offers physicians and care teams real-time visibility and control, enhancing the overall treatment process.
The company’s growth is not only reflected in its innovative solutions but also in its expanded leadership team, which includes domain experts in product development, regulatory affairs, clinical strategy, and commercialization. Mark Pacyna, with his extensive experience from Medtronic, leads this team, and the series A funding reaffirms the belief in Reprieve’s potential to revolutionize heart failure treatment globally.
Jan Garfinkle, Founding and Managing Partner of Arboretum Ventures, expressed excitement about Reprieve’s emergence from stealth mode, highlighting the pivotal trial ahead. The series A funding signifies a collective belief in Reprieve’s team and the necessity for technology that can significantly impact the lives of ADHF patients worldwide.
Reprieve Cardiovascular, headquartered in Milford, Massachusetts, is on a mission to bring intelligence to decongestion management, providing hope for more than 25 million heart failure patients globally. The ongoing FASTR trial is a testament to the company’s commitment to advancing innovative therapies and transforming heart failure care.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.
